ATE447414T1 - Verwendung aktivierter polymere zur trennung von protein- und polypeptid-multimeren - Google Patents

Verwendung aktivierter polymere zur trennung von protein- und polypeptid-multimeren

Info

Publication number
ATE447414T1
ATE447414T1 AT06706962T AT06706962T ATE447414T1 AT E447414 T1 ATE447414 T1 AT E447414T1 AT 06706962 T AT06706962 T AT 06706962T AT 06706962 T AT06706962 T AT 06706962T AT E447414 T1 ATE447414 T1 AT E447414T1
Authority
AT
Austria
Prior art keywords
separate protein
activated polymers
polypeptide multimers
polypeptide
separate
Prior art date
Application number
AT06706962T
Other languages
English (en)
Inventor
Andreas Wolf
Patrick Hoffmann
Nee Henckel Hepp
Tobias Raum
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Application granted granted Critical
Publication of ATE447414T1 publication Critical patent/ATE447414T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
AT06706962T 2005-02-16 2006-02-15 Verwendung aktivierter polymere zur trennung von protein- und polypeptid-multimeren ATE447414T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05003332 2005-02-16
PCT/EP2006/001359 WO2006087178A1 (en) 2005-02-16 2006-02-15 Use of activated polymers for separation of protein and polypeptide multimers

Publications (1)

Publication Number Publication Date
ATE447414T1 true ATE447414T1 (de) 2009-11-15

Family

ID=36168573

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06706962T ATE447414T1 (de) 2005-02-16 2006-02-15 Verwendung aktivierter polymere zur trennung von protein- und polypeptid-multimeren

Country Status (12)

Country Link
US (1) US20080312411A1 (de)
EP (1) EP1848458B1 (de)
JP (1) JP2008530163A (de)
AT (1) ATE447414T1 (de)
AU (2) AU2006215823A1 (de)
CA (1) CA2594666A1 (de)
DE (1) DE602006010176D1 (de)
DK (1) DK1848458T3 (de)
ES (1) ES2335304T3 (de)
HR (1) HRP20090594T1 (de)
SI (1) SI1848458T1 (de)
WO (1) WO2006087178A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5766118B2 (ja) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
ES2623262T3 (es) 2012-12-14 2017-07-10 Purdue Pharma Lp Derivados de morfinano que contienen nitrógeno y el uso de los mismos
WO2014091297A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Spirocyclic morphinans and their use
EP2931724B1 (de) 2012-12-14 2017-01-25 Purdue Pharma LP Pyridonmorphinananaloga und biologische wirkung auf opioidrezeptoren
WO2014102587A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. 7,8-cyclicmorphinan analogs
US8946255B2 (en) 2012-12-28 2015-02-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
AU2013369037C1 (en) 2012-12-31 2017-06-08 Rhodes Technologies Process for preparing 7beta-substituted 6alpha,14alpha -ethenomorphinans and 7beta-substituted 6alpha,14alpha-ethanomorphinans
WO2015097548A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
EP3089978B1 (de) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridonsulfonmorphinan-analoga als opioidrezeptorliganden
ES2926580T3 (es) 2016-12-23 2022-10-27 Minoryx Therapeutics S L Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma
AU2019224127B2 (en) 2018-02-23 2021-12-09 Rhodes Technologies Novel opioid compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312808A (en) * 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
EP2295450B1 (de) * 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegyliertes interleukin 10
CN101426511A (zh) * 2001-06-22 2009-05-06 法马西亚公司 化学修饰的祖细胞生成素连接物

Also Published As

Publication number Publication date
US20080312411A1 (en) 2008-12-18
DK1848458T3 (da) 2010-02-01
WO2006087178A1 (en) 2006-08-24
HRP20090594T1 (hr) 2009-12-31
EP1848458B1 (de) 2009-11-04
CA2594666A1 (en) 2006-08-24
ES2335304T3 (es) 2010-03-24
SI1848458T1 (sl) 2010-01-29
JP2008530163A (ja) 2008-08-07
AU2007237199A1 (en) 2008-01-17
EP1848458A1 (de) 2007-10-31
AU2006215823A1 (en) 2006-08-24
DE602006010176D1 (de) 2009-12-17

Similar Documents

Publication Publication Date Title
ATE447414T1 (de) Verwendung aktivierter polymere zur trennung von protein- und polypeptid-multimeren
ATE498412T1 (de) System zur abgabe von flüchtigen stoffen
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
ATE525033T1 (de) Optische sonde zur abgabe von licht
CY1119751T1 (el) Υλικα και μεθοδοι για θεραπεια ή προληψη ασθενειων που σχετιζονται me her-3
ATE531374T1 (de) Vorrichtung auf polymerbasis mit verzögerter freisetzung
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
WO2007104062A3 (en) Compositions and methods based on peptide binding profiling
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
CR11504A (es) Deteccion mejorada de la expresion de mage-a
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EA201171494A1 (ru) Миметики белка smac
EA201000327A1 (ru) Белок
ATE506861T1 (de) Molkenproteinträger zur abgabe von aktivsubstanzen
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
CY1120055T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1119930T1 (el) Λευκολεκτινες και χρησεις αυτων
DE602005012555D1 (de) Künstliches protein zur absoluten quantifizierung von proteinen und verwendungen davon
DE602007001103D1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
CY1114618T1 (el) Βιολογικα δραστικα πεπτιδια που περιεχουν καρβοξυτελικη αργινινη
ATE484201T1 (de) Verwendung von beta-cryptoxanthin
ATE472317T1 (de) Kosmetische verwendung von molkeproteinmizellen
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
DE602006008892D1 (de) Kompaktes system zur verpackung von injizierbaren gungen
DE602005027400D1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes, hyperlipidämie, hyperglykämie und insulinresistenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1848458

Country of ref document: EP